Pharma BD Deal Intelligence
$69 per share all-cash offer represents immediate and certain value and a significant premium for Genzyme shareholders — 38% over Genzyme's unaffected share…
Genzyme management rejected the $69-per-share hostile bid as undervalued; CEO Henri Termeer argued shareholders deserved closer to $80 per share, saying 'They…
Sanofi paid $315M to settle claims it slowed Lemtrada's development to avoid CVR payouts of $708M-$3.8B; FDA approval missed targets by 8+ months and sales…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Sanofi-aventis submitted a non-binding proposal to acquire Genzyme for approximately $18.5B ($69/share) on August 29, 2010. Final definitive agreement reached February 16, 2011 at $74/share plus CVR (~$20.1B total). Closed April 8, 2011.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Genzyme Corporation (this deal) | 2010 | $18.5B | 75 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
| Sanofi SA / Protein Sciences Corp. | 2017 | $650M | 72 |
← Browse all deals · How we score deals
More: 2010 deals · Sanofi SA deals · Neurology deals